Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial [0.03%]
BRAF和MEK短程联合抑制，以及单药或与抗CD20免疫治疗联用治疗复发/难治性套细胞淋巴瘤：一项研究者发起的多中心II期临床试验
Luca De Carolis,Monia Capponi,Alessandro Mancini et al.
Luca De Carolis et al.
Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia [0.03%]
高剂量利妥昔单抗和低剂量阿卡替尼治疗慢性淋巴细胞白血病的疗效研究
Charles C Chu,Clare B Heffernan,Nydia C Jaimes-Delgadillo et al.
Charles C Chu et al.
Anti-CD20 monoclonal antibodies (mAbs) are effective but not curative treatment for chronic lymphocytic leukemia (CLL). To study rituximab efficacy, we examined serial blood samples from CLL patients receiving initial monotherapy with high-...
Expansion and safety profile of CD28-costimulated anti-CD19 CAR T cells in B-cell lymphoma versus autoimmune disease [0.03%]
共刺激抗CD19嵌合抗原受体T细胞（CAR-T）在B细胞淋巴瘤和自身免疫性疾病中的扩增及安全性研究
Mirjeta Berisha,Denise Walther,Martin Böttcher et al.
Mirjeta Berisha et al.
From monoclonal to polyfunctional immunotherapy: Reprogramming CAR-T-cell therapy with oncolytic viruses in B-cell malignancies [0.03%]
从单克隆到多功能免疫疗法：用溶瘤病毒重组CAR-T细胞治疗B细胞肿瘤
Eduard Achim,Guy Ungerechts,Ciprian Tomuleasa et al.
Eduard Achim et al.
Alice Ibbotson,Simon Crouch,Jacqueline Ferrari et al.
Alice Ibbotson et al.
Dysregulated innate immunity contributes to clonal cytopenias and myeloid neoplasms, but its extent across disease stages and clinical relevance remain incompletely defined. We analyzed plasma ASC/NLRP3 double-positive (DP) specks, ASC sing...
Should flow cytometry be required for CMML diagnosis? Position of the ELN iMDS Flow Working Group [0.03%]
流式细胞术是否应作为CMML诊断的必需条件？ELN iMDS流式工作组立场文件
Orianne Wagner-Ballon,Leonie Saft,Ulrika Johansson et al.
Orianne Wagner-Ballon et al.
Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma [0.03%]
伊代卡巴泰尤塞与内源性T细胞表型与复发多发性骨髓瘤无进展生存期的关联研究
Bruno Paiva,Irene Manrique,Ethan Thompson et al.
Bruno Paiva et al.
Improved understanding of how chimeric antigen receptor (CAR) and endogenous T-cell phenotypes associate with progression-free survival (PFS) is needed to individualize and improve immunotherapy outcomes in multiple myeloma (MM). We charact...
Nahia Gómez-Echarte,Edurne San José-Enériz,Estíbaliz Urizar-Compains et al.
Nahia Gómez-Echarte et al.
A comprehensive understanding of the molecular mechanisms underlying multiple myeloma (MM) pathogenesis is essential for developing therapeutic strategies that overcome disease heterogeneity and treatment relapse. In this review, we focus o...
Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany [0.03%]
德国使用cilta-cel治疗多发性骨髓瘤的CAR-T门诊转化：首次临床见解
Christof Scheid,Philipp Gödel,Christopher Krone et al.
Christof Scheid et al.
Genome-wide association study in 21,271 individuals identifies 9 novel loci associated with circulating CD34+ hematopoietic stem and progenitor cell levels [0.03%]
在21,271人中开展的全基因组关联研究确定了9个与循环CD34+造血干细胞和祖细胞水平相关的新型位点
Yuwen Xie,Antton Lamarca,Caterina Cafaro et al.
Yuwen Xie et al.